Abstract | BACKGROUND AND OBJECTIVES: Whether iron supplementation in patients on hemodialysis could be delivered by less frequent but higher single doses compared with the currently more common higher-frequency schedules of lower single iron doses is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: RESULTS: In total, 108 patients completed the study. At 40 weeks, hemoglobin changed by -0.27 g/dl (95% confidence interval, -0.64 to 0.09) in the iron sucrose arm and by -0.74 g/dl (95% confidence interval, -1.1 to -0.39) in the ferric carboxymaltose arm compared with baseline. Noninferiority was not established in the per-protocol population as hemoglobin changes compared with baseline differed by -0.47 g/dl (95% confidence interval, -0.95 to 0.01) in the ferric carboxymaltose arm compared with the iron sucrose arm. Proportional changes from baseline to week 40 differed by -31% (98.3% confidence interval, -52 to -0.1) for ferritin, by 1% (98.3% confidence interval, -7 to 10) for transferrin, and by -27% (98.3% confidence interval, -39 to -13) for transferrin saturation in the ferric carboxymaltose arm compared with the iron sucrose arm. Erythropoiesis-stimulating agent dosing did not differ between groups. The overall number of adverse events was similar; however, more infections were observed in the iron sucrose arm. CONCLUSIONS: CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:
|
Authors | Bernhard Bielesz, Matthias Lorenz, Rossella Monteforte, Thomas Prikoszovich, Michaela Gabriel, Michael Wolzt, Andreas Gleiss, Walter H Hörl, Gere Sunder-Plassmann |
Journal | Clinical journal of the American Society of Nephrology : CJASN
(Clin J Am Soc Nephrol)
Vol. 16
Issue 10
Pg. 1512-1521
(10 2021)
ISSN: 1555-905X [Electronic] United States |
PMID | 34470831
(Publication Type: Comparative Study, Equivalence Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 by the American Society of Nephrology. |
Chemical References |
- Biomarkers
- Ferric Compounds
- Hematinics
- Hemoglobins
- Transferrin
- ferric carboxymaltose
- Maltose
- Ferritins
- Ferric Oxide, Saccharated
|
Topics |
- Adult
- Aged
- Anemia, Iron-Deficiency
(blood, diagnosis, etiology, prevention & control)
- Austria
- Biomarkers
(blood)
- Drug Administration Schedule
- Female
- Ferric Compounds
(administration & dosage, adverse effects)
- Ferric Oxide, Saccharated
(administration & dosage, adverse effects)
- Ferritins
(blood)
- Hematinics
(administration & dosage, adverse effects)
- Hemoglobins
(metabolism)
- Humans
- Infusions, Intravenous
- Male
- Maltose
(administration & dosage, adverse effects, analogs & derivatives)
- Middle Aged
- Prospective Studies
- Renal Dialysis
(adverse effects)
- Renal Insufficiency, Chronic
(blood, diagnosis, therapy)
- Time Factors
- Transferrin
(metabolism)
- Treatment Outcome
|